Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: Sclerostin is a negative regulator of bone formation. OBJECTIVE: The aim of the study was to compare serum sclerostin levels in premenopausal and postmenopausal women and evaluate its relationship to estrogen, TH, bone turnover, and bone mass. DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional observational study of healthy community-dwelling pre- and postmenopausal women. INTERVENTION(S): There were no interventions. MAIN OUTCOME MEASURE(S): We compared serum sclerostin levels in pre- and postmenopausal women and correlated sclerostin levels with female sex hormones, calciotropic hormones, bone turnover markers, and bone mineral density. RESULTS: Premenopausal women were 26.8 yr old, and postmenopausal women were 56.8 yr old. Postmenopausal women had lower values for estradiol (30 +/- 23 vs. 10 +/- 4 pg/ml; P < 0.001), estrone (61 +/- 24 vs. 29 +/- 10 pg/ml; P <0.001), and free estrogen index (FEI) (6 +/- 4 vs. 3 +/- 2 pmol/nmol; P = 0.008) and significantly lower bone mineral density at all sites compared to premenopausal women, with no significant differences in levels of PTH, 25-hydroxy or 1,25-dihydroxy vitamin D levels. Postmenopausal women had significantly higher serum sclerostin levels (1.16 +/- 0.38 ng/ml vs. 0.48 +/- 0.15 ng/ml; P < 0.001). Because most of the premenopausal women were on oral contraceptives, subsequent analyses were limited to postmenopausal women. There were significant negative correlations between sclerostin and FEI and sclerostin and PTH in this group. Using multiple regression analysis, both FEI (beta = -0.629; P = 0.002) and PTH (beta = -0.554; P = 0.004) were found to be independent predictors of sclerostin levels in postmenopausal women. CONCLUSIONS: Our findings suggest that serum sclerostin levels are regulated by both estrogens and PTH in postmenopausal women. These findings need to be explored further in larger prospective studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling in Development and Disease
Clevers, H. (2006) · Cell · doi:10.1016/j.cell.2006.10.018 · Cited by 5,568
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602 · cited 2×
“They also evaluated SOST mRNA expression in the bones of 11-month-old osteopenic, estrogen-deprived ovariectomized rats after 8 wk of systemic, intermittent administration of 5 g/kg of PTH (1-34).”
Day, T. F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.03.016 · Cited by 1,616
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“They also evaluated SOST mRNA expression in the bones of 11-month-old osteopenic, estrogen-deprived ovariectomized rats after 8 wk of systemic, intermittent administration of 5 g/kg of PTH (1-34).”
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Riggs, B. L., Khosla, S., & Melton, L. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.763 · Cited by 1,143
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling:Arrows point the way
He, X., Semenov, M., Tamai, K., & Zeng, X. (2004) · Development · doi:10.1242/dev.01117 · Cited by 1,044
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
Cited by
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
A systematic review of vitamin D status in populations worldwide
Hilger, J., Friedel, A., Herr, R., Rausch, T., Roos, F., Wahl, D. A., Pierroz, D. D., Weber, P., & Hoffmann, K. (2014) · British Journal of Nutrition · doi:10.1017/s0007114513001840 · Cited by 832
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Tu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 397
Osteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
“In particular, elevation of parathyroid hormone (PTH), either in an intermittent or a continuous mode, downregulates sclerostin expression in osteocytes in mice and decreases the circulating levels of the protein in humans (11;26-29) (Figure 3).”
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
“214 Kim et al. found that estrogen 17 β -Estradiol (E2) suppressed the SOST expression induced by BMP2, but increases the expression and activation levels of β -catenin in osteoblasts.”
BackgroundThe Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
The clinical utility of bone marker measurements in osteoporosis
Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K., & van Laar, J. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-201 · Cited by 322
“Serum SCL levels are regulated by both estrogens and PTH in postmenopausal women [53].”
BackgroundCirculating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2186 · Cited by 311
A global representation of vitamin D status in healthy populations
Wahl, D. A., Cooper, C., Ebeling, P. R., Eggersdorfer, M., Hilger, J., Hoffmann, K., Josse, R., Kanis, J. A., Mithal, A., Pierroz, D. D., et al. (2012) · Archives of Osteoporosis · doi:10.1007/s11657-012-0093-0 · Cited by 311
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2958 · Cited by 272
Bone turnover markers: use in osteoporosis
Naylor, K., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 262
The osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Regulation of circulating sclerostin levels by sex steroids in women and in men
Mödder, U. I., Clowes, J. A., Hoey, K., Peterson, J. M., McCready, L., Oursler, M. J., Riggs, B. L., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.128 · Cited by 229
“The recent development of immunoassays for sclerostin led to the observation by Mirza and colleagues((20)) that postmenopausal women had higher serum sclerostin levels than premenopausal women, and in postmenopausal women, serum sclerostin levels were inversely associated with the circulating free estradiol (E2) index.”
MethodResultThe WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
Benisch, P., Schilling, T., Klein-Hitpass, L., Frey, S. P., Seefried, L., Raaijmakers, N., Krug, M., Regensburger, M., Zeck, S., Schinke, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045142 · Cited by 208
“Direct connections between the protein and osteoporosis have already been described: serum levels of Sclerostin were found enhanced in postmenopausal women [41] and one of the upcoming treatments for osteoporosis is the application of antiSclerostin-antibodies [24,42].”
BackgroundEffects of PTH on osteocyte function
Bellido, T., Saini, V., & Pajevic, P. D. (2013) · Bone · doi:10.1016/j.bone.2012.09.016 · Cited by 196
Shi, T., Shen, S., Shi, Y., Wang, Q., Zhang, G., Lin, J., Chen, J., Bai, F., Zhang, L., Wang, Y., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00989-x · Cited by 87
Hormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77
“Using an in-house assay developed at Amgen, Mirza and colleagues [25] initially studied pre- and postmenopausal women and reported significantly higher serum sclerostin levels in the postmenopausal women.”
MethodEffect of liver dysfunction on circulating sclerostin
Rhee, Y., Kim, W. J., Han, K. J., Lim, S. K., & Kim, S. H. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0524-z · Cited by 42
Silverman, S. L. (2010) · Journal of Osteoporosis · doi:10.4061/2010/941419 · Cited by 30
“Serum sclerostin levels are significantly higher in postmenopausal women than in premenopausal women with significant negative correlations between free estrogen levels and sclerostin as well as PTh and sclerostin [8].”
BackgroundOne year B and D vitamins supplementation improves metabolic bone markers
Herrmann, W., Kirsch, S. H., Kruse, V., Eckert, R., Gräber, S., Geisel, J., & Obeid, R. (2013) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2012-0599 · Cited by 29
Metadata
- Authors
- Mirza, F. S., Padhi, I. D., Raisz, L. G., & Lorenzo, J. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-04-01
- Volume
- 95
- Issue
- 4
- Pages
- 1991-1997
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2051748491
- Cited by
- 311
- References
- 26
- FWCI
- 28.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.